How to appeal a Cigna spinal muscular atrophy denial
ACA §2719 + ERISA §503 · 180-day window · 30-day decision
To appeal a Cigna spinal muscular atrophy denial, file an internal appeal within 180 days of the date on the denial letter through Cigna's member or provider portal, under ACA §2719 + ERISA §503. Cigna returns standard decisions in 30 days; if it upholds the denial you can request an independent external review within 4 months.
The framework that applies to your appeal
Federal law gives you the right to a full and fair internal appeal, then an external review by an independent third party.
Cigna-specific note: Sold its Medicaid Advantage book to HCSC in 2023. Express Scripts (PBM) is Cigna-owned. Frequent class-action litigation around mental health parity.
What Cigna's policy requires for spinal muscular atrophy
Cited policy: Cigna / Express Scripts Risdiplam (Evrysdi) PA
Genetically confirmed 5q SMA (biallelic SMN1). Age >=2 wk per May 2022 label. Daily oral. Reauth at 12 mo with motor function (CHOP-INTEND, HFMSE, MFM-32, RULM) showing stability/improvement. Not concurrent with Spinraza. Tablet formulation for >=2 yr / >=20 kg.
How Cigna denies spinal muscular atrophy — and how to counter it
Where Cigna pushes back: 1) Step-therapy: must fail Spinraza first; 2) Pre-symptomatic infants under 2 mo — RAINBOWFISH 'experimental'; 3) Adult Type 3/4 — insufficient evidence; 4) Switching from Spinraza without prior failure.
Counter-arguments that hold up: FIREFISH NEJM 2021 (Darras) — Type 1 infants 29% sat >=5 sec at 12 mo; SUNFISH Lancet Neurol 2022 (Mercuri) — Type 2/3 ages 2-25 yr MFM-32 +1.36 vs -0.19 placebo. RAINBOWFISH supported May 30, 2022 label expansion to >=2 wk neonates (Finkel) — NOT experimental, FDA-approved indication. JEWELFISH switcher cohort (Spinraza-, Zolgensma-, olesoxime-experienced + adults) showed safety and motor stability — supports switching for oral preference, scoliosis fusion limiting IT access, or convenience. Step-therapy ignores mechanism (oral systemic SMN2 splicing modifier vs IT ASO).
What Cigna typically denies for spinal muscular atrophy
Across Cigna's commercial and Medicare books, denials cluster around a small number of patterns. For spinal muscular atrophy, expect:
- Mental health parity violations
- Step therapy
- Specialty drug prior auth
- OON balance billing disputes
Treatments most often denied in this category
These are the spinal muscular atrophy treatments most often flagged for prior auth, step therapy, or medical necessity review:
- Spinraza (nusinersen)
- Evrysdi (risdiplam)
- Zolgensma (onasemnogene)
- Combination/sequential
- Switching therapy
- BiPAP / NIV
How to submit the appeal to Cigna
- Read the denial letter — note the exact denial reason code and the appeal deadline (180 days from the date on the letter).
- Gather supporting documentation: physician letter of medical necessity, relevant clinical notes, peer-reviewed citations supporting the treatment for your indication, and the policy or coverage document Cigna cited in the denial.
- File the appeal through Cigna's portal (members: https://my.cigna.com ; providers: https://cignaforhcp.cigna.com). Standard decision returns within 30 days; expedited urgent appeals return within 72 hours.
- If denied again, request external review by an independent reviewer within 4 months of the final internal denial. In CT, the state insurance department coordinates external review for fully-insured plans; ERISA self-funded plans use a federal external review through DOL/EBSA.
Clinician or prior-auth team handling this on the practice side? See Cigna's prior-authorization criteria by drug: Cigna PA criteria on ApprovalHelp.
Frequently asked questions
How long do I have to appeal a Cigna spinal muscular atrophy denial?
Cigna allows 180 days from the date on the denial letter to file an internal appeal. Standard decisions come back within 30 days; expedited decisions for urgent care typically within 72 hours.
What's the fastest way to submit a Cigna appeal?
Members can submit through the Cigna member portal at https://my.cigna.com. Providers should use the provider portal at https://cignaforhcp.cigna.com. Faxed and mailed appeals are accepted but take longer.
What denials does Cigna most often issue for spinal muscular atrophy?
For spinal muscular atrophy, Cigna most often denies on: 1) Step-therapy: must fail Spinraza first; 2) Pre-symptomatic infants under 2 mo — RAINBOWFISH 'experimental'; 3) Adult Type 3/4 — insufficient evidence; 4) Switching from Spinraza without prior failure. The strongest counters: FIREFISH NEJM 2021 (Darras) — Type 1 infants 29% sat >=5 sec at 12 mo; SUNFISH Lancet Neurol 2022 (Mercuri) — Type 2/3 ages 2-25 yr MFM-32 +1.36 vs -0.19 placebo. RAINBOWFISH supported May 30, 2022 label expansion to >=2 wk neonates (Finkel) — NOT experimental, FDA-approved indication. JEWELFISH switcher cohort (Spinraza-, Zolgensma-, olesoxime-experienced + adults) showed safety and motor stability — supports switching for oral preference, scoliosis fusion limiting IT access, or convenience. Step-therapy ignores mechanism (oral systemic SMN2 splicing modifier vs IT ASO).
What if Cigna denies the appeal too?
After an internal appeal denial you have the right to an external review by an independent reviewer (IRO) — request it within 4 months of the final internal denial.
Related appeal guides
Start your Spinal muscular atrophy appeal
Upload your Cigna denial letter — DenialHelp drafts a physician-ready appeal in five minutes, aligned to ACA §2719 + ERISA §503.
Get started →Contact: hello@denialhelp.com